News

Combining p38i Inhibition and OX40 Agonist: Potential Therapy for Metastatic Breast Cancer

Does the Time From Breast Cancer Diagnosis to Primary Surgery Impact Overall Survival? Researchers Say Yes

FDA Brief: Update on Mammography Regulations

Update on FDA Safety Alert for Skin Cancer in Scar Tissue Around Breast Implants

Oncolytic Virus Plus Neoadjuvant Chemotherapy Under Study in Triple-Negative Breast Cancer

FDA Brief: Expanded Indication for Adjuvant Abemaciclib in High-Risk Breast Cancer

Variability in Breast Cancer Risk Classification Models Indicates Need to Improve Predictability

TILs Versus Gene-Expression Signatures: Which Has Greater Prognostic Value in Early-Stage Breast Cancer?

Understanding Intratumor Heterogeneity in Triple-Negative Breast Cancer

Adding Dual Immune Blockade to Chemotherapy for HER2-Negative Breast Cancer

TALENT Trial: Neoadjuvant T-DXd for HER2-Low, HR-Positive Breast Cancer

Sacituzumab Govitecan-hziy Approved by the FDA for HR-Positive, HER2-Negative Breast Cancer

T-DXd Versus Conventional Regimens for T-DM1–Pretreated, HER2-Positive Metastatic Breast Cancer

FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer

Role of Biomarker in Predicting and Driving Brain Metastasis in Inflammatory Breast Cancer

Adding Capivasertib to Fulvestrant for Advanced Hormone Receptor–Positive Breast Cancer

5-Year Follow-up on Role of Circulating Tumor Cell Count in Metastatic Breast Cancer

Outcomes With Sacituzumab Govitecan by Trop-2 Expression in Metastatic Breast Cancer

Platinum Plus Standard Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy for Aggressive Breast Cancer

An Index of Sensitivity to Endocrine Therapy Under Study in Male Breast Cancer

Racial Disparities in Clinical Outcomes of Hormone Receptor–Positive Breast Cancer

SABCS 2022: Mechanisms of Resistance to CDK4/6 Inhibitors in Aggressive Breast Cancer

SABCS 2022: Camizestrant Versus Fulvestrant for Hormone Receptor–Positive, HER2-Negative Breast Cancer

SABCS 2022: Can Patients With Hormone Receptor–Positive Breast Cancer Interrupt Endocrine Therapy for Pregnancy?

SABCS 2022: Does the Duration of Prior CDK4/6 Inhibition Impact Outcomes After Estrogen Receptor Degradation?

SABCS 2022: Breast-Conserving Therapy May Benefit Some Patients With Multiple Ipsilateral Breast Cancer

SABCS 2022: Survival Update From DESTINY-Breast03 on T-DXd Versus T-DM1 in HER2-Positive Breast Cancer

SABCS 2022: Risk of Contralateral Breast Cancer Among Carriers of Germline Pathogenic Variants

SABCS 2022: Update From First-in-Human Trial of ARV-471 in Advanced Breast Cancer

SABCS 2022: monarchE Update on Endocrine Therapy Plus Abemaciclib for High-Risk Breast Cancer

Do High-Deductible Health Plans Discourage Patients From Additional Testing After an Abnormal Mammogram?

SABCS 2022: Adding Everolimus to Adjuvant Endocrine Therapy for High-Risk Breast Cancer

SABCS 2022: Long-Term Update From TAILORx in Early-Stage Breast Cancer

SABCS 2022: 10-Year Update on Role of Low-Dose Tamoxifen in Noninvasive Breast Cancer

Can Novel Intratumoral Injection Convert Early-Stage Breast Cancers Into Immunogenic Tumors?

EBCC 2022: Study Reports Benefits of Ultrasound-Guided Surgery for Ductal Carcinoma In Situ

SITC 2022: Is IL-17 the Culprit Behind Resistance to CDK4/6 Inhibitors in HER2-Positive Breast Cancer?

Early-Phase Trial of Olaparib With Radiotherapy for Triple-Negative Breast Cancer

EBCC 2022: Tumor-Infiltrating Lymphocyte Levels and Outcomes in HER2-Positive Breast Cancer

ASTRO 2022: Long-Term Outcomes With a Three-Fraction Partial-Breast Irradiation Strategy

EBCC 2022: Are Changes in Blood Proteins an Early Signal of Breast Cancer?

SITC 2022: Neoantigen-Specific Antibody Responses in Metastatic Triple-Negative Breast Cancer

EBCC 2022: Risk Prediction Model and Individualizing Breast Cancer Screening Strategies

SITC 2022: Neoadjuvant Combination of Radiotherapy and Pembrolizumab in Triple-Negative Breast Cancer

ASTRO 2022: Can Regional Node Irradiation Reduce Risk for Locoregional Breast Cancer Recurrence?

ASTRO 2022: Phase III Trial Compares 3 Versus 6 Weeks of Radiation Therapy for Early-Stage Breast Cancer

Dose-Dense Adjuvant Chemotherapy in Early-Stage Breast Cancer: 15-Year Italian Trial Update

Identifying Genomic Characteristics of Breast Cancers Linked to PTEN Hamartoma Tumor Syndrome

ASTRO 2022: Radiation Dose and Long-Term Lymphedema Risk in Patients With Breast Cancer

ASTRO 2022: Final Study Results With Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer

Can a Silicone-Based Polyurethane Film Dressing Prevent Acute Radiation Dermatitis in Breast Cancer?

Darolutamide for AR-Positive, Advanced Triple-Negative Breast Cancer: Phase II Study Results

Adding Palbociclib to Standard Adjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer: 20-Year Trial Update

Can Hand Cooling and Compression Prevent Nerve Pain in Patients With Breast Cancer?

Neoadjuvant Endocrine Therapy for Breast Cancer: Differential Responses in Black Versus White Women

Phase III DAWNA-2 Trial: Dalpiciclib Plus Endocrine Therapy for Advanced Breast Cancer

FDA Brief: Priority Review for Sacituzumab Govitecan in HR-Positive, HER2-Negative Metastatic Breast Cancer

ASCO Quality 2022: Causes of Variation in Receipt of Axillary Surgery in Older Patients With Breast Cancer

Blocking CD73 With Oleclumab in Combination Therapy for Triple-Negative Breast Cancer

ASCO Quality 2022: Survey Identifies Knowledge Gaps in Breast Cancer Screening Practices for Transgender People

Patterns of Genomic Instability and Resistance to Endocrine Therapy in Metastatic Breast Cancer

ESMO 2022: Biomarker Analyses Focus on Resistance to T-DXd in Metastatic Breast Cancer